IIT Bombay, Indian Drug Manufacturers’ Association (IDMA) and Organisation of Pharmaceutical Producers of India (OPPI) jointly organised a One-day Workshop On ‘Unmet Needs in Drug Delivery Technologies’ organized as a part of N. R. Kamath Chair Professorship on 25th February, 2017. Prof. Samir Mitragotri, the first NR Kamath Chair Professor was the keynote speaker for the event. “Researchers in the field of drug discovery and the pharmaceutical industry must work together to bridge the gap in the existing drug development process” was the main focus of the this workshop. The Seminar was chaired by Padma Vibhushan Dr. R. A. Mashelkar, National Research Professor, and Mentor of the Prof. N. R. Kamath Chair.
The main objective of this workshop was to identify the gaps and challenges in drug delivery technologies. It also aimed at understanding the recent technological advances in the field, including strategies for oral, topical/transdermal and targeted drug delivery for applications in oncology, cardiovascular diseases, infectious diseases and CNS disorders etc. Prof. Samir Mitragotri, stressed the importance to incorporate drug delivery technologies in the earlier phases of drug development. He also claimed that institutes and researchers worked towards innovations in drug discovery without giving much importance to how the drug is administered for which he strongly suggests that active collaboration between research institutes and industry is required.
Prof. Jonathan Dordick, Vice President for Research and Howard P. Isermann Professor of Chemical and Biological Engineering, Biomedical Engineering, Materials Science and Engineering, and Biology at Rensselaer Polytechnic Institute (RPI) also delivered a keynote address at the conference. Prof. Dordick talked about the challeges in drug delivery and the need for academic and practioner research communities to work together to address the health challenges.
In addition to faculty members and academic researchers, the workshop participants included 70 research leaders from 30 drug and pharmceutical companies.